Results 51 to 60 of about 4,032 (162)
ABSTRACT Human T‐lymphotropic viruses 1 and 2 (HTLV‐1 and HTLV‐2) were first isolated from patients with hematological malignancies. This study was the first to investigate the frequency of HTLV‐1 and its molecular diversity among patients with hematolymphoid cancers who were treated at a leading reference hospital in Pará, northern Brazil.
Gabriel dos Santos Pereira Neto +8 more
wiley +1 more source
What's new? TRIM25 is known for its role in antiviral immunity and association with poor prognosis in various cancers. This study reveals an association between high TRIM25 expression and Merkel cell polyomavirus positivity in Merkel cell carcinoma.
Klaus W. Fagerstedt +6 more
wiley +1 more source
Merkel cell carcinoma (MCC) is a rare malignancy with aggressive behavior mostly seen in the elderly and immunosuppressed patients. In 2008, the clonal integration of a new human polyomavirus, named Merkel cell polyomavirus (MCPyV), was found to be ...
Wen-Tsao Ho +4 more
doaj +1 more source
An Accurate Genetic Colocalisation Method for the HLA Locus
ABSTRACT Genetic colocalisation analyses are frequently conducted to determine if causal signals at a genetic locus are shared between two phenotypes. However, colocalisation is rarely undertaken at the HLA locus, due to its complex linkage disequilibrium (LD) and high polymorphism density.
Guillaume Butler‐Laporte +18 more
wiley +1 more source
Merkel Cell Carcinoma: The Past, the Present, and the Future
Since the first description of the Merkel cell carcinoma by Cyril Toker in 1972, the number of studies has significantly increased over the last 4 decades.
Inamaria Erovic, Boban M. Erovic
doaj +1 more source
Current In Vitro and In Vivo Models to Study MCPyV-Associated MCC
Merkel cell polyomavirus (MCPyV) is the only human polyomavirus currently known to cause human cancer. MCPyV is believed to be an etiological factor in at least 80% of cases of the rare but aggressive skin malignancy Merkel cell carcinoma (MCC). In these
Amanda S. W. Loke +2 more
doaj +1 more source
Neoadjuvant therapy in skin cancer: current evidence and future perspectives
Summary The development of immune checkpoint inhibitors and targeted therapies has fundamentally changed the treatment of cutaneous malignancies, especially in squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The latest neoadjuvant approaches have shown promising results in locally advanced stages.
Lea Daniello +2 more
wiley +1 more source
The Murky Life of Merkel Cell Polyomavirus [PDF]
Merkel cell polyomavirus (MCPyV) expressing viral T antigens is a common feature of most Merkel cell carcinomas, a primary neuroendocrine skin tumor. MCPyV has been difficult to propagate in vitro. In this issue of Cell Host & Microbe, Liu et al. (2016) report that human dermal fibroblasts support productive MCPyV infection.
openaire +2 more sources
RNA‐Sequencing Reveals Two Subgroups of Eccrine Porocarcinomas and Poromas
ABSTRACT Eccrine porocarcinoma (EPC), a rare malignant eccrine gland tumour, remains molecularly understudied. Transcriptomic studies of EPC and benign eccrine poroma (EP) have identified recurrent fusions and expression changes, but differences distinguishing malignant EPC from benign EP are unclear.
Maya Puttonen +6 more
wiley +1 more source
Merkel cell carcinoma with seborrheic keratosis: A unique association
Merkel cell carcinoma (MCC) is a rare, clinically aggressive neuroendocrine carcinoma of the skin; MCC is 40 times less common as compared to melanoma. The most frequently reported sites have been the head and neck, extremities, and trunk.
Murthy S Anand +3 more
doaj +1 more source

